The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells / Cretella, D., Ravelli, A., Fumarola, C., LA MONICA, S., Digiacomo, G., Cavazzoni, A., Alfieri, R., Biondi, A., Generali, D., Bonelli, M., Petronini, P.G.. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 37:(2018), pp. 72-83. [10.1186/s13046-018-0741-3]
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
Daniele Cretella;Andrea Ravelli;Claudia Fumarola
;Silvia La Monica;Graziana Digiacomo;Andrea Cavazzoni;Roberta Alfieri;Alessandra Biondi;Mara Bonelli;Pier Giorgio Petronini
2018-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
